The city of Dallas, Texas, currently has 266 active clinical trials seeking participants for Cancer research studies.
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
NCT05710848
Recruiting
This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Non-muscle-invasive Bladder Cancer
Register for Updates
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
NCT06517212
Recruiting
This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk early breast cancer patients with obesity or overweight, inhibiting the growth and survival of micrometastatic disease and leading to clearance of tumor-informed circulating tumor DNA (ctDNA) and freedom from the development of metastatic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas
Conditions: Breast Cancer, Breast Neoplasms, Breast Cancers
Register for Updates
GammaPod Registry and Quality of Life Nomogram
NCT03562273
Recruiting
This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a single-fraction boost with the GammaPod.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: UTSouthwestern, Dallas, Texas
Conditions: Breast Cancer Female
Register for Updates
Abatacept in Immune Checkpoint Inhibitor Myocarditis
NCT05335928
Recruiting
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Myocarditis Acute, Cancer
Register for Updates
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811
Recruiting
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Renovatio Clinical, Dallas, Texas +1 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix
NCT05197881
Recruiting
This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Terminology Cri... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Cervical Cancer by FIGO Stage 2018
Register for Updates
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
NCT05919108
Recruiting
This phase II trial tests how well neratinib prior to the primary treatment (neoadjuvant) works in treating patients with stage I-III HER2 mutated lobular breast cancers. Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving neratinib in addition to normal therapy may work better in treating cancer than the endocrine therapy patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: University of Texas, Southwestern, Dallas, Texas
Conditions: Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
Register for Updates
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
NCT06026332
Recruiting
Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world setting
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Ferring Investigation Site, Dallas, Texas
Conditions: Bladder Cancer
Register for Updates
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985
Recruiting
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Register for Updates
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
NCT06136884
Recruiting
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, Endometrial Cancer
Register for Updates
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
NCT05693766
Recruiting
This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Invasive Mammary Carcinoma, Metastatic Breast Cancer
Register for Updates
Customized TULSA-PRO Ablation Registry
NCT05001477
Recruiting
This patient registry will capture data from patients who have been or who are undergoing the transurethral ultrasound ablation (TULSA) procedure as part of their routine clinical care. The registry will shed light on real-world outcomes of safety and efficacy of the procedure and understand how a patient's quality of life is affected throughout their follow-up and lifetime.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Benign Prostatic Hyperplasia
Register for Updates